Christopher Ma

Assistant Professor

University of Calgary

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

ORCID

Google Scholar

About

Christopher Ma is an Assistant Professor at the University of Calgary, Canada. His research primarily focuses on inflammatory bowel disease, including the management of ulcerative colitis and Crohn's disease, with particular interest in the integration of clinical tools and technology in patient care. Recent articles by Professor Ma explore the impact of COVID-19 on care practices, the efficacy of biologics, and the development of digital tools to enhance patient self-management.

Christopher Ma

Research Interests

Explore related searches

Contact this professor

About

Articles (29)

Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study

Navigating Care Amid Crisis: The Impact of the COVID-19 Pandemic on Eosinophilic Esophagitis Management in Canada

Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn’s Disease: Opportunities and Challenges

Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials

Mirikizumab for Crohn’s Disease: Small Step Forward or Giant Leap Ahead?

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease

Developing and Evaluating a Bundled Digital Tool to Improve Complex Care and Self-Management of Patients With Inflammatory Bowel Disease: Protocol for a Hybrid Effectiveness-Implementation Study

Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study

Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion

Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy

Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales. Authors' reply

Eosinophilic Esophagitis: Seeing Only the Tip of the Iceberg

Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn’s Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials

Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis

Re-evaluating Methods for Assessing Differences in Response in Ileal vs Colonic Crohn’s Disease: A Post-hoc Analysis of the FITZROY Trial

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply

Meta‐analysis: Intestinal ultrasound to evaluate colonic contents and constipation

The Future of Clinical Trials in Inflammatory Bowel Disease

Scoring Indices for Perianal Fistulising Crohn’s Disease: A Systematic Review

Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study

Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration

Postendoscopy Care for Patients Presenting With Esophageal Food Bolus Impaction: A Population-Based Multicenter Cohort Study

Systematic review and meta‐analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis

Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials

Mirikizumab for the treatment of moderate to severe ulcerative colitis

Targeting IL-23 for IBD: Rationale and Progress to Date

Lack of Benefit for Early Escalation to Advanced Therapies in Ulcerative Colitis: Critical Appraisal of Current Evidence

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis

Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis

Collaborators (11)

Ritu Verma

Johan Burisch

Frank Hoentjen

Eileen Crowley

Sunil Samnani

Yuhong Yuan

ROCIO SEDANO

Elizabeth Spencer

Virginia Solitano

Yasmin Nasser

Farhad Peerani

How do I reach out?

Meet Kite AI